D. Boral Capital Reaffirms “Buy” Rating for Hoth Therapeutics (NASDAQ:HOTH)
Hoth Therapeutics (NASDAQ:HOTH – Get Free Report)‘s stock had its “buy” rating restated by research analysts at D. Boral Capital in a report issued on Tuesday,Benzinga reports. They presently have a $5.00 target price on the stock. D. Boral Capital’s price target suggests a potential upside of 338.60% from the stock’s previous close. Separately, HC […]
Hoth Therapeutics (NASDAQ:HOTH – Get Free Report)‘s stock had its “buy” rating restated by research analysts at D. Boral Capital in a report issued on Tuesday,Benzinga reports. They presently have a $5.00 target price on the stock. D. Boral Capital’s price target suggests a potential upside of 338.60% from the stock’s previous close. Separately, HC […]
